Adalimumab biosimilar - Boehringer Ingelheim
At a glance
- Drug Originator Boehringer Ingelheim
- Drug Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
- USA Patent Applicants BOEHRINGER INGELHEIM
- USA Patents 1
- BLAs 1
- International Patents 4
Disclaimer